Global Tay-Sachs Disease Pipeline Insights, 2019 Report - ResearchAndMarkets.com

DUBLIN--()--The "Tay-Sachs Disease - Pipeline Insight, 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Tay-Sachs Disease - Pipeline Insight, 2019 report outlays comprehensive insights of present scenario and growth prospects across the indication.

A detailed picture of the Tay - Sachs disease pipeline landscape is provided which includes the disease overview and Tay - Sachs disease treatment guidelines. The assessment part of the report embraces, in depth Tay - Sachs disease commercial assessment and clinical assessment of the pipeline products under development.

In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Tay-Sachs Disease collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Tay - Sachs disease Pipeline Development Activities

The report provides insights into different therapeutic candidates in discovery and preclinical, phase 1, phase 2, and phase 3 stage. Drugs under development as a monotherapy or combination therapy are also included. It also analyses key players involved in Tay - Sachs disease targeted therapeutics development with respective active and inactive (dormant or discontinued) projects with the appropriate reasons if available. Tay - Sachs disease pipeline report covers 6+ companies. Some of the key players include IntraBio Inc (IB1001-201), Castle Creek Pharmaceuticals (CCP 010) etc.

Tay - Sachs disease Analytical Perspective

In-depth Tay-Sachs Disease Commercial Assessment of products

This report provides an in-depth Commercial Assessment of therapeutic drugs have been included which comprises of collaborations, Licensing, Acquisition -Deal Value Trends. The sub-segmentation is described in the report which includes Company-Company Collaborations (Licensing/Partnering), Company-Academia Collaborations, and Acquisition analysis in both Graphical and tabulated form.

Tay-Sachs Disease Clinical Assessment of products

The report comprises of comparative clinical assessment of products by development stage, product type, route of administration, molecule type, and MOA type across this indication.

Key Topics Covered:

1. Report Introduction

2. Tay-Sachs Disease (GM2 gangliosidosis, type 1, HexA deficiency, Hexosaminidase A deficiency, Hexosaminidase alpha-subunit deficiency (variant B))

2.1. Tay-Sachs Disease Disease Overview

2.2. Tay-Sachs Disease History

2.3. Tay-Sachs Disease Symptoms

2.4. Tay-Sachs Disease Causes

2.5. Tay-Sachs Disease Pathophysiology

2.6. Tay-Sachs Disease Diagnosis

2.6.1. Diagnostic Guidelines

3. Tay-Sachs Disease Current Treatment Patterns

3.1. Treatment Guidelines

4. Tay-Sachs Disease- An Analytical Perspective

4.1. In-depth Commercial Assessment

4.1.1. Tay-Sachs Disease companies collaborations, Licensing, Acquisition -Deal Value Trends

4.1.1.1. Assessment Summary

4.1.2. Tay-Sachs Disease Collaboration Deals

4.1.2.1. Company-Company Collaborations (Licensing/Partnering) Analysis

4.1.2.2. Tay-Sachs Disease Acquisition Analysis

4.2. Clinical Assessment of Pipeline Drugs

4.2.1. Assessment by Phase of Development

4.2.2. Assessment by Product Type (Mono/Combination)

4.2.2.1. Assessment by Stage and Product Type

4.2.3. Assessment by Route of Administration

4.2.3.1. Assessment by Stage and Route of Administration

4.2.4. Assessment by Molecule Type

4.2.4.1. Assessment by Stage and Molecule Type

4.2.5. Assessment by MOA

4.2.5.1. Assessment by Stage and MOA

5. Tay-Sachs Disease Pipeline Therapeutics

5.1. Late Stage Products (Phase-III)

5.1.1. Comparative Analysis

5.2. Mid Stage Products (Phase-II)

5.2.1. Comparative Analysis

5.3. Early Stage Products (Phase-I)

5.3.1. Comparative Analysis

5.4. Pre-clinical and Discovery Stage Products

5.4.1. Comparative Analysis

5.5. Inactive Products

6. Tay-Sachs Disease-Products Analysis

6.1. Product Profiles

6.1.1. IB1001-201- IntraBio

6.1.1.1. Product Description

6.1.1.1.1. Product Overview

6.1.1.1.2. Mechanism of Action

6.1.1.2. Research and Development

6.1.1.2.1. Clinical Studies

6.1.1.2.1.1. Detailed Study Description

6.1.1.2.1.2. Study Results

6.1.1.2.1.3. Clinical Trials: Tabular View

6.1.1.3. Product Development Activities

6.1.1.3.1. Tabulated Product Summary

6.1.1.3.1.1. General Description Table

6.1.2. CCP 010- Castle Creek Pharmaceuticals

7. Recent Technologies

8. Tay-Sachs Disease Key Companies

8.1. Axovant Gene Therapies

8.2. Actelion Pharmaceuticals

8.3. Castle Creek Pharmaceuticals

8.4. Avigen

8.5. Gene Therapy Research Institution

8.6. Oxford Glycobiology Institute

9. Tay-Sachs Disease Key Products

9.1. AXO AAV GM2

9.2. Miglustat

9.3. CCP 010

9.4. Lysosomal storage disease gene therapy

9.5. Research programme: Tay-Sachs disease gene therapy

9.6. Acetylleucine

10. Dormant and Discontinued Products

10.1. Dormant Products

10.1.1. Reasons for being dormant

10.2. Discontinued Products

10.2.1. Reasons for the discontinuation

11. Tay-Sachs Disease- Unmet Needs

12. Tay-Sachs Disease- Future Perspectives

13. Appendix

Companies Mentioned

  • Axovant Gene Therapies
  • IntraBio
  • Actelion Pharmaceuticals
  • Castle Creek Pharmaceuticals
  • Avigen
  • Gene Therapy Research Institution
  • Oxford Glycobiology Institute
  • Amicus Therapeutics
  • Aldagen
  • Recursion Pharmaceuticals

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/g2phka

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900